From the results, we selected Sorafenib for further characterization as an inhibitor of necroptosis, not only because it protected against different necroptosis inducing stimuli but also because it is an FDA-approved drug that is used in clinic to treat advanced hepatocellular carcinoma,46 renal cell carcinoma47 and AML.27 Several necroptosis inhibitors have been discovered or designed to target RIPK1,5, 48 RIPK349 and MLKL,50, 51 the core necroptosis pathway,52 but none of them are already in clinical use.53 Sorafenib is not the only anti-cancer drug that can inhibit necroptosis. Here, RIPK1 is linked to acute myeloid leukemia.